FAKTOR OPTIONSSCHEIN - GENMAB | Market Closed - Boerse Frankfurt Warrants 15:21:05 14/06/2024 BST | ||
| 15.06 EUR | -0.99% |
|
| Current month | +25.19% | ||
| 1 month | +42.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 15.06 | -0.99% |
| 13/06/24 | 15.21 | +5.77% |
| 12/06/24 | 14.38 | +6.91% |
| 11/06/24 | 13.45 | +6.24% |
| 10/06/24 | 12.66 | +0.72% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 03:21 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PN4GMS |
| ISIN | DE000PN4GMS1 |
| Date issued | 10/11/2021 |
| Strike | 1,824 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 30 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 95.6 € |
|---|---|
| Lowest since issue | 4.54 € |
| Spread | 0.08 € |
| Spread % | 0.53% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832
DKK
Average target price
2,464
DKK
Spread / Average Target
+34.46%
- Stock Market
- Certificates
- Certificat
